JP6539206B2 - 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用 - Google Patents

肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用 Download PDF

Info

Publication number
JP6539206B2
JP6539206B2 JP2015529082A JP2015529082A JP6539206B2 JP 6539206 B2 JP6539206 B2 JP 6539206B2 JP 2015529082 A JP2015529082 A JP 2015529082A JP 2015529082 A JP2015529082 A JP 2015529082A JP 6539206 B2 JP6539206 B2 JP 6539206B2
Authority
JP
Japan
Prior art keywords
beta
agonist
pulmonary
selective
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015529082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526497A (ja
JP2015526497A5 (cg-RX-API-DMAC7.html
Inventor
カベサ ボルハ イバニェス
カベサ ボルハ イバニェス
アナ ガルシア−アルバレス
アナ ガルシア−アルバレス
カルジャ バレンティン フステル
カルジャ バレンティン フステル
Original Assignee
セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ (エフェ.エセ.ペ.)
セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ (エフェ.エセ.ペ.)
ホスピタル クリニック デ バルセロナ
ホスピタル クリニック デ バルセロナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ (エフェ.エセ.ペ.), セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ (エフェ.エセ.ペ.), ホスピタル クリニック デ バルセロナ, ホスピタル クリニック デ バルセロナ filed Critical セントロ ナショナル デ インベスティガシオネス カルディオバスキュラレス カルロス テルセーロ (エフェ.エセ.ペ.)
Publication of JP2015526497A publication Critical patent/JP2015526497A/ja
Publication of JP2015526497A5 publication Critical patent/JP2015526497A5/ja
Application granted granted Critical
Publication of JP6539206B2 publication Critical patent/JP6539206B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015529082A 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用 Expired - Fee Related JP6539206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201231343 2012-08-29
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
PCT/ES2013/070611 WO2014033343A1 (es) 2012-08-29 2013-08-28 Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Publications (3)

Publication Number Publication Date
JP2015526497A JP2015526497A (ja) 2015-09-10
JP2015526497A5 JP2015526497A5 (cg-RX-API-DMAC7.html) 2016-10-13
JP6539206B2 true JP6539206B2 (ja) 2019-07-03

Family

ID=47520452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529082A Expired - Fee Related JP6539206B2 (ja) 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用

Country Status (6)

Country Link
US (1) US10532038B2 (cg-RX-API-DMAC7.html)
EP (1) EP2891490B1 (cg-RX-API-DMAC7.html)
JP (1) JP6539206B2 (cg-RX-API-DMAC7.html)
DK (1) DK2891490T3 (cg-RX-API-DMAC7.html)
ES (2) ES2394349B1 (cg-RX-API-DMAC7.html)
WO (1) WO2014033343A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
EP4313019A4 (en) * 2021-03-31 2025-02-12 B3AR Therapeutics, Inc. Compositions of micronized solabegron and methods of use
IT202300021417A1 (it) 2023-10-13 2025-04-13 Univ Pisa Agonisti o attivatori del recettore adrenergico beta-3

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
US4338333A (en) 1979-06-16 1982-07-06 Beecham Group Limited Ethanamine derivatives their preparation and use in pharmaceutical compositions
ATE1899T1 (de) 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
PT82120B (en) 1985-03-01 1988-06-16 Beecham Group Plc Process for preparing veterinary formulations containing ethanolamine derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
IT1204416B (it) 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ATE144139T1 (de) 1989-06-13 1996-11-15 Sanofi Sa Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
GB8925032D0 (en) 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
ATE185564T1 (de) 1992-08-31 1999-10-15 Sankyo Co Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
JP3100165B2 (ja) 1994-11-29 2000-10-16 大日本製薬株式会社 インドール誘導体
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ES2158996T3 (es) 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1997025311A1 (en) 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
IL131130A0 (en) 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
AU735249B2 (en) 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
HUP0301329A2 (hu) 2000-07-13 2003-08-28 Eli Lilly And Co. Béta3 Adrenergiás agonisták, valamint ezen vegyületeket tartalmazó gyógyászati készítmények és eljárás e vegyületek előállítására
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US20040242485A1 (en) 2003-05-30 2004-12-02 Takashi Kadowaki Compositions and methods for the amelioration of leptin resistance
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
CN102764438A (zh) 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途

Also Published As

Publication number Publication date
ES2394349B1 (es) 2013-11-04
US10532038B2 (en) 2020-01-14
EP2891490B1 (en) 2020-12-09
JP2015526497A (ja) 2015-09-10
EP2891490A1 (en) 2015-07-08
ES2863749T3 (es) 2021-10-11
ES2394349A1 (es) 2013-01-30
DK2891490T3 (da) 2021-03-15
WO2014033343A1 (es) 2014-03-06
WO2014033343A9 (es) 2014-04-24
US20150374655A1 (en) 2015-12-31
ES2394349A8 (es) 2013-04-25

Similar Documents

Publication Publication Date Title
JP2022542514A (ja) 脳卒中の処置のためのmek阻害剤
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
JP7159302B2 (ja) 線維性疾患の治療のための方法
JP2014077022A (ja) メタボリックシンドローム、2型糖尿病、肥満又は糖尿病前症の治療的処置方法
KR20070009746A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와pdev 억제제의 상승작용 조합물
JP2011503045A (ja) Crth2拮抗化合物の使用
AU2022404695B2 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
MX2013005705A (es) Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes.
JP2019521964A (ja) アドレナリン受容体調節化合物およびその使用方法
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
WO2014090990A1 (en) Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
JP2015526497A (ja) 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用
AU2025205402A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP4609877B2 (ja) 慢性拒絶反応抑制剤
TW200303214A (en) Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
JP2006503025A (ja) p38MAPキナーゼの抑制による疼痛治療
JP4942297B2 (ja) 肺高血圧症の処置を目的としたn−{5−[4−(4−メチルピペラジノメチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリジン−アミンの使用
JP2007506784A (ja) 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用
JP2016506918A (ja) イソメテプテン異性体
KR102587177B1 (ko) 우울증 치료를 위한 펜옥시프로필아민 화합물의 용도
KR20080108156A (ko) 유기 화합물의 조합물
JP2025511786A (ja) 筋線維症の治療
JP2010513414A (ja) アリスキレン及びアボセンタンを使用する医薬組成物
US20210308138A1 (en) Tissue transglutaminase modulators for medicinal use
US20110034504A1 (en) Agent for preventing and/or treating vascular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190607

R150 Certificate of patent or registration of utility model

Ref document number: 6539206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees